| D008810 |
Mice, Inbred C57BL |
One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. |
Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse |
|
| D009409 |
Nerve Crush |
Treatment of muscles and nerves under pressure as a result of crush injuries. |
Crush, Nerve |
|
| D004305 |
Dose-Response Relationship, Drug |
The relationship between the dose of an administered drug and the response of the organism to the drug. |
Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response |
|
| D000818 |
Animals |
Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. |
Animal,Metazoa,Animalia |
|
| D012165 |
Retinal Ganglion Cells |
Neurons of the innermost layer of the retina, the internal plexiform layer. They are of variable sizes and shapes, and their axons project via the OPTIC NERVE to the brain. A small subset of these cells act as photoreceptors with projections to the SUPRACHIASMATIC NUCLEUS, the center for regulating CIRCADIAN RHYTHM. |
Cell, Retinal Ganglion,Cells, Retinal Ganglion,Ganglion Cell, Retinal,Ganglion Cells, Retinal,Retinal Ganglion Cell |
|
| D014409 |
Tumor Necrosis Factor-alpha |
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. |
Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha |
|
| D051379 |
Mice |
The common name for the genus Mus. |
Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus |
|
| D018345 |
Mice, Knockout |
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes. |
Knockout Mice,Mice, Knock-out,Mouse, Knockout,Knock-out Mice,Knockout Mouse,Mice, Knock out |
|
| D018696 |
Neuroprotective Agents |
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. |
Neuroprotectant,Neuroprotective Agent,Neuroprotective Drug,Neuroprotectants,Neuroprotective Drugs,Neuroprotective Effect,Neuroprotective Effects,Agent, Neuroprotective,Agents, Neuroprotective,Drug, Neuroprotective,Drugs, Neuroprotective,Effect, Neuroprotective,Effects, Neuroprotective |
|
| D020221 |
Optic Nerve Injuries |
Injuries to the optic nerve induced by a trauma to the face or head. These may occur with closed or penetrating injuries. Relatively minor compression of the superior aspect of orbit may also result in trauma to the optic nerve. Clinical manifestations may include visual loss, PAPILLEDEMA, and an afferent pupillary defect. |
Optic Nerve Trauma,Optic Neuropathy, Traumatic,Second Cranial Nerve Trauma,Cranial Nerve II Injuries,Optic Nerve Avulsion,Optic Nerve Contusion,Optic Nerve Transection,Second Cranial Nerve Injuries,Trauma, Second Cranial Nerve,Avulsion, Optic Nerve,Avulsions, Optic Nerve,Contusion, Optic Nerve,Contusions, Optic Nerve,Injuries, Optic Nerve,Injury, Optic Nerve,Nerve Avulsion, Optic,Nerve Avulsions, Optic,Nerve Contusion, Optic,Nerve Contusions, Optic,Nerve Injuries, Optic,Nerve Injury, Optic,Nerve Transection, Optic,Nerve Transections, Optic,Nerve Trauma, Optic,Nerve Traumas, Optic,Neuropathies, Traumatic Optic,Neuropathy, Traumatic Optic,Optic Nerve Avulsions,Optic Nerve Contusions,Optic Nerve Injury,Optic Nerve Transections,Optic Nerve Traumas,Optic Neuropathies, Traumatic,Transection, Optic Nerve,Transections, Optic Nerve,Trauma, Optic Nerve,Traumas, Optic Nerve,Traumatic Optic Neuropathies,Traumatic Optic Neuropathy |
|
-transparent.png){kind=logo}
